Latest Breaking News On - A sinclair dunlop - Page 1 : comparemela.com

Short Interest in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Expands By 16.1%

Short Interest in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Expands By 16.1%
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

Arizona
United-states
Timothy-eugene-sullivan
A-sinclair-dunlop
First-horizon-advisors-inc
Nasdaq
News-ratings-for-apellis-pharmaceuticals-daily
Needham-company
Citigroup
Securities-exchange-commission
Institutional-investors-weigh-in-on-apellis-pharmaceuticals
Apellis-pharmaceuticals-inc

Apellis Pharmaceuticals (NASDAQ:APLS) Issues Earnings Results, Meets Expectations

Apellis Pharmaceuticals (NASDAQ:APLS) Issues Earnings Results, Meets Expectations
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

A-sinclair-dunlop
Robertw-baird
Adamj-townsend
Apellis-pharmaceuticals
Apellis-pharmaceuticals-stock-performance
Apellis-pharmaceuticals-inc
Securities-exchange-commission
Insider-activity-at-apellis-pharmaceuticals
Jpmorgan-chase-co
News-ratings-for-apellis-pharmaceuticals-daily
Goldman-sachs-group

UBS Group Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $85.00

UBS Group Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $85.00
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United-states
American
Adamj-townsend
Robertw-baird
A-sinclair-dunlop
Raymond-james
Charles-schwab-investment-management-inc
Apellis-pharmaceuticals
Needham-company
Profund-advisors
Apellis-pharmaceuticals-stock-down
Securities-exchange-commission

Analysts Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Target Price at $78.60

Analysts Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Target Price at $78.60
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

A-sinclair-dunlop
Raymond-james
Timothy-eugene-sullivan
Analyst-recommendations-for-apellis-pharmaceuticals
Goldman-sachs-group
First-horizon-advisors-inc
Apellis-pharmaceuticals
News-ratings-for-apellis-pharmaceuticals-daily
Apellis-pharmaceuticals-inc
Financial-wealth-managment
Us-bancorp
Covestor-ltd

Apellis Pharmaceuticals' (APLS) "Neutral" Rating Reaffirmed at Mizuho

Apellis Pharmaceuticals' (APLS) "Neutral" Rating Reaffirmed at Mizuho
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states
America
Adamj-townsend
Robertw-baird
A-sinclair-dunlop
Us-bancorp
Analyst-recommendations-for-apellis-pharmaceuticals
News-ratings-for-apellis-pharmaceuticals-daily
Apellis-pharmaceuticals-company-profile
Stephens-consulting
Covestor-ltd